Ariana Pelosci

A phase 2 trial examining the use of small molecule immunomodulator EC-18 in patients with head and neck cancer experiencing chemoradiation-induced oral mucositis met its primary and secondary end points.

The FDA issued a complete response letter to the company responsible for developing narsoplimab because of the inability to estimate treatment effects on patients receiving hematopoietic stem cell transplant–associated thrombotic microangiopathy.

Patients with high-risk smoldering myeloma who were treated with carfilzomib, lenalidomide, and dexamethasone and lenalidomide maintenance experienced an improvement in minimal residual disease–negative complete response and could have delayed end-organ disease.

The FDA approved atezolizumab for treatment of stage II to IIIA non–small cell lung cancer following resection and platinum-based chemotherapy.

The addition of temozolomide to vincristine and irinotecan appears to be a new standard of care for adult and pediatric patients with relapsed/refractory rhabdomyosarcoma, according to the European Paediatric Soft Tissue Sarcoma Group.

Investigators identified a correlation between financial toxicity significant differences in mental and physical quality of life, and patient satisfaction with breast reconstruction among patients with breast cancer.

Patients with colorectal liver metastases who were treated with transarterial Yttrium-90 radioembolization plus second-line chemotherapy experienced a long-term survival benefit.

Patients with small cell lung cancer who failed first-line treatment within 6 months were examined for efficacy of anlotinib plus chemotherapy in a phase 2 trial whose results were presented at the 2021 ESMO Congress.

Ibrutinib for treating patients with chronic lymphocytic leukemia increased the risk of atrial fibrillation, bleeding, and heart failure in results of a cohort study.

An interim analysis indicated that dalpiciclib plus pyrotinib yielded promising results in patients with HER2-positive advanced stage breast cancer.

Andrew Armstrong, MD, MSc, spoke about key findings, patient crossover, and takeaways from the ARCHES trial for metastatic hormone-sensitive prostate cancer.

Men with metastatic hormone-sensitive prostate cancer who were treated with enzalutamide plus androgen deprivation therapy experienced an improved, long-lasting overall survival compared with those who received placebo.

Patients who were treated with ramucirumab plus gemcitabine experienced improved overall survival compared with patients treated with gemcitabine plus placebo.

Patients with previously untreated metastatic uveal melanoma who also harbored HLA-A*02:01 and were treated with tebentafusp experienced a longer overall survival compared with the control group of a phase 3 clinical trial.

Adding venetoclax to cladribine, high-dose cytarabine, and idarubicin appears to yield high rates of minimal residual disease negativity and promising survival in patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.

Patients with recurrent or metastatic cervical cancer treated with cemiplimab experienced an improved overall survival, progression-free survival, and overall response rate, leading to priority review from the FDA.

An association was identified between second-line clinical trial participation for patients with metastatic non–small cell lung cancer and a mean cost savings of $6663 for health care payers.

Patients with muscle-invasive bladder cancer treated with gemcitabine and split-dose cisplatin plus pembrolizumab experienced improved pathological downstaging.

Refractory gastrointestinal stromal tumors can potentially be treated by using a KIT inhibitor combination of PLX9486 and sunitinib.

A recent trial found that patients with EGFR exon 20 insertion–mutant metastatic non–small cell lung cancer with prior disease control on standard EGFR inhibitors demonstrated efficacy and tolerability of mobocertinib.

Patients with testicular cancer who are treated with platinum-based chemotherapy or radiotherapy have an increased risk of mortality unrealted to their disease.

The FDA approved the use of the Pfizer COVID-19 vaccine for patients of a specific age, at risk jobs, or with serious health conditions.

Results from the phase 3 eXalt3 study indicated that ensartinib led to a longer progression-free survival and intracranial response rate compared with crizotinib for patients with ALK-positive non-small cell lung cancer.

The toxicity profiles of PD-1 and PD-L1 inhibitors displayed unique characteristics when combines with other agents such as chemotherapy, targeted therapy, and immunotherapy.

Pembrolizumab plus chemotherapy compared with the placebo plus chemotherapy demonstrated an improvement in overall survival and progression-free survival for patients with esophageal squamous cell carcinoma.

Patients undergoing implant-based or autologous reconstruction and received adjuvant or neoadjuvant chemotherapy did not have an association with likelihood of complications compared with those who did not undergo chemotherapy.

Patients who were carriers of pathogenic variants of for BRCA1/2 had a better physical and mental quality of life after undergoing risk-reducing salpingectomy compared with risk-reducing salpingo-oophorectomy.

The latest episode of CancerNetwork®’s podcast examines an initiative to diversify patient populations in oncology clinical trials and increase accessibility to these opportunities.

With the combination of mobocertinib and T-DM1, potent preclinical efficacy was observed in lung cancer cells with HER2 exon 20 insertion mutations.

The use of onvansertib in combination with standard-of-care chemotherapy had an increase in the objective response rate and progression-free survival during the phase 1b/2 trial for metastatic colorectal cancer.